Septerna (SEPN) Stock Price, News & Analysis

Company Overview

Septerna, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address. Septerna’s investigational pipeline includes oral GPCR modulators, including SEP-786, an oral parathyroid hormone 1 receptor agonist being developed for the potential treatment of hypoparathyroidism.

Septerna was founded by scientists with expertise in GPCR biology and drug discovery and is headquartered in San Diego, California. The company has no marketed products and is advancing its candidates through clinical development and research activities intended to support treatments for patients in the United States and other global markets. Patrick Horn, Ph.D., serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $35.77 to $38.73
• 50-Day Range: $34.98 to $48.19
• 52-Week Range: $17.55 to $51.10
• Volume: 349,431 shs
• Average Volume: 419,343 shs
• Market Capitalization: $1.79 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.44
• Consensus Rating: Moderate Buy

Septerna Stock Analysis - MarketRank™

Septerna scored higher than 55% of companies evaluated by MarketBeat, and ranked 416th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Septerna has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Septerna has a consensus price target of $52.44, representing about 36.7% upside from its current price of $38.37.

Amount of Analyst Coverage

Septerna has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Septerna are expected to decrease in the coming year, from ($1.41) to ($2.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Septerna is -71.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Septerna is -71.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Septerna has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.04% of the float of Septerna has been sold short.

Short Interest Ratio / Days to Cover

Septerna has a short interest ratio ("days to cover") of 8.8.

Change versus previous month

Short interest in Septerna has recently increased by 6.99%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Septerna does not currently pay a dividend.

Dividend Growth

Septerna does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: N/A

News Sentiment

Septerna has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Septerna this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Septerna to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Septerna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,341,010.00 in company stock.

Percentage Held by Insiders

5.80% of the stock of Septerna is held by insiders.

Percentage Held by Institutions

Septerna has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SEPN
• Previous Symbol: NASDAQ:SEPN
• CIK: 1984086
• Web: septerna.com
• Phone: (650) 338-3533
• Fax: N/A
• Employees: 130
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Septerna: $52.44
• High Price Target: $62.00
• Low Price Target: $43.00
• Potential Upside/Downside: +36.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.88 million
• Net Margins: -24.51%
• Pretax Margin: -23.17%
• Return on Equity: -9.57%
• Return on Assets: -6.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.99
• Quick Ratio: 4.99

Sales & Book Value

• Annual Sales: $45.95 million
• Price / Sales: 38.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.53 per share
• Price / Book: 4.50

Miscellaneous

• Outstanding Shares: 46,680,000
• Free Float: 43,970,000
• Market Cap: $1.79 billion
• Optionable: N/A
• Beta: 2.29